Following identification of the therapeutic effect of glucagon-like peptide-1 (GLP-1), the dipeptidyl-peptidase-4 (DPP-4) inhibitors were developed specifically to delay its rapid degradation in plasma, and hence to enhance the incretin effect in type 2 diabetes (1, –, 3). Here, GCG is linked to type 2 diabetes mellitus.